Capstone Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Capstone Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$3.61M	Sell	7,357 -775	-10%	-$339K	0.1%	237
2017 Q1	$3.15M	Sell	8,132 -165	-2%	-$61.2K	0.09%	272
2016 Q4	$3.05M	Sell	8,297 -1,265	-13%	-$481K	0.09%	274
2016 Q3	$3.84M	Sell	9,562 -79	-0.8%	-$31.7K	0.11%	213
2016 Q2	$3.37M	Buy	9,641 +592	+7%	+$228K	0.1%	234
2016 Q1	$3.26M	Buy	9,049 +372	+4%	+$153K	0.09%	270
2015 Q4	$4.71M	Buy	8,677 +949	+12%	+$514K	0.14%	180
2015 Q3	$3.6M	Buy	7,728 +378	+5%	+$203K	0.11%	220
2015 Q2	$3.75M	Sell	7,350 -356	-5%	-$174K	0.11%	237
2015 Q1	$3.48M	Buy	7,706 +136	+2%	+$57.6K	0.1%	256
2014 Q4	$3.11M	Buy	7,570 +905	+14%	+$356K	0.09%	277
2014 Q3	$2.4M	Sell	6,665 -58	-0.9%	-$19.4K	0.08%	284
2014 Q2	$1.9M	Sell	6,723 -1,085	-14%	-$322K	0.06%	363
2014 Q1	$2.35M	Sell	7,808 -913	-10%	-$281K	0.07%	323
2013 Q4	$2.4M	Sell	8,721 -5,073	-37%	-$1.46M	0.07%	325
2013 Q3	$4.32M	Buy	13,794 +584	+4%	+$154K	0.1%	212
2013 Q2	$2.97M	Buy	+13,210	New	+$3.08M	0.08%	281

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Capstone Asset Management's REGN Position: Q2 2017 in Review

Capstone Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 9.5% in Q2 2017, selling an estimated $339K and leaving 7,357 shares worth $3.61M. The position accounts for 0.1% of the portfolio, ranked #237.

Capstone Asset Management first reported a position in REGN in Q2 2013 and has held it in 17 quarters since. The position peaked at $4.71M in Q4 2015. 603 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

Capstone Asset Management held 7,357 shares of Regeneron Pharmaceuticals worth $3.61M as of Q2 2017.
Capstone Asset Management sold 775 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $339K.
Regeneron Pharmaceuticals made up 0.1% of Capstone Asset Management's portfolio in Q2 2017, its #237 holding.
Capstone Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Capstone Asset Management's Regeneron Pharmaceuticals position peaked at $4.71M in Q4 2015.
603 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.